European research organization Fraunhofer announces a product that's able to quickly, easily detect the deadly ailment

With almost all cancers, early detection is the key to survivability. This is especially true with prostate cancer, which has a nearly 100% survival rate if caught early enough. A prototype set to be demonstrated by the Fraunhofer organization may make such early detection more common and reliable than ever before.

Although the device, named the OCD device still requires a full biopsy to get a tissue sample, the time and effort required from there is exponentially smaller than the best current methods. It's capable of visually analyzing the tissue sample and determining within ninety seconds whether the sample is malignant or benign. It works like this:

$15 provides access to this article and every case-study, interview, and analysis piece that we publish for the next 30 days. Our Premium Subscription also provides access to a database of over 100,000 articles on innovation in brand, customer, and retail experience.
Already a subscriber? Log in